Shortfall Happens

The dark side of outsourcing is coming into view: worldwide capacity for biological manufacturing is currently maxed out. Firms with biological products still in clinical development could find their progress to market delayed, if they can't make enough protein for trials. Others unable to meet demand for approved products will have to reconcile themselves to lost sales. Demand will likely exceed capacity for several years to come--putting companies that do have manufacturing capacity in strong bargaining positions.

The biotechnology industry has embraced outsourcing in recent years, seeing it as a practical way to focus investment and limit risk. Supposedly sager biotechs let go of the vision of becoming FIPCOS (fully-integrated pharmaceutical companies), deciding that money was better spent on R&D or acquisitions, than on capital intensive capacities that could be had for hire. And the fear factor also kicked in: if a product failed or fell behind, a costly manufacturing plant or purpose-built sales team would be left sitting idle, burning vital cash. Firms that outsourced were praised for their parsimony, while those that bucked the trend—like ImClone Systems Inc. , which decided to build its own manufacturing plant, were criticized for doing so.

But now the dark side of outsourcing is coming into focus. Worldwide capacity for biological manufacturing is maxed out. Firms...

More from Business Strategy

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.